Status:
COMPLETED
Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial
Lead Sponsor:
Kaiser Permanente
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Evidence exists to support low-grade inflammation as the inciting factor leading to visceral hypersensitivity and alteration in motility in irritable bowel syndrome.In the medical literature,there is ...
Eligibility Criteria
Inclusion
- Patients from the hospitals and clinics of the Southern California Permanente Medical Group who conform to the Rome III criteria and
- Age 18 years and above,
- Male or female,
- Able to give consent and follow the treatment plan and be able to answer surveys.
- Negative serum pregnancy test (females of childbearing potential only) and are willing to use an adequate method of contraception throughout the duration of the study.
Exclusion
- Any of the following: diabetes, HIV disease, use of anticoagulants or antiplatelet medication, abnormal coagulation or thrombocytopenia, biliary obstruction, inflammatory bowel, symptomatic gallstones, celiac disease, ongoing use of medications known to cause or exacerbate symptoms of IBS and chronic, daily users of IBS medications.
- Use of scheduled IBS medications for 4 weeks prior to and during the treatment period.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00779493
Start Date
November 1 2008
End Date
June 1 2009
Last Update
March 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente
Los Angeles, California, United States, 90027